Luc Truyen
One of our biggest learnings, after several efforts that didn’t yield the result that we hope for, was that we probably wanted to intervene much earlier. We see there is…
DetailsOne of our biggest learnings, after several efforts that didn’t yield the result that we hope for, was that we probably wanted to intervene much earlier. We see there is…
DetailsThis project has numerous advantages over current approaches. These include the excellent pre-trial characterisation of research participants to inform selection and reduce screen failure, the establishment of the highest possible…
DetailsPreventing the development of dementia in biomarker-positive people would be a fantastic step forward in our fight against Alzheimer’s disease. The EPAD and its novel trial concept will hopefully help…
DetailsEPAD is part of a global initiative that will make a fundamental difference to the understanding and management of Alzheimer’s disease in people with very early or no symptoms at…
Details